Free Trial
NYSE:CRL

Charles River Laboratories International (CRL) Stock Price, News & Analysis

Charles River Laboratories International logo
$156.58 -0.91 (-0.58%)
As of 11:25 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Charles River Laboratories International Stock (NYSE:CRL)

Key Stats

Today's Range
$156.51
$158.72
50-Day Range
$114.71
$157.50
52-Week Range
$91.86
$254.15
Volume
80,822 shs
Average Volume
1.02 million shs
Market Capitalization
$7.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$171.85
Consensus Rating
Hold

Company Overview

Charles River Laboratories International Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

CRL MarketRank™: 

Charles River Laboratories International scored higher than 81% of companies evaluated by MarketBeat, and ranked 223rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Charles River Laboratories International has received a consensus rating of Hold. The company's average rating score is 2.19, and is based on 4 buy ratings, 11 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Charles River Laboratories International has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Charles River Laboratories International's stock forecast and price target.
  • Earnings Growth

    Earnings for Charles River Laboratories International are expected to grow by 17.52% in the coming year, from $9.36 to $11.00 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Charles River Laboratories International is -241.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Charles River Laboratories International is -241.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Charles River Laboratories International has a PEG Ratio of 5.23. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Charles River Laboratories International has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Charles River Laboratories International's valuation and earnings.
  • Percentage of Shares Shorted

    5.38% of the float of Charles River Laboratories International has been sold short.
  • Short Interest Ratio / Days to Cover

    Charles River Laboratories International has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Charles River Laboratories International has recently increased by 7.85%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Charles River Laboratories International does not currently pay a dividend.

  • Dividend Growth

    Charles River Laboratories International does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.38% of the float of Charles River Laboratories International has been sold short.
  • Short Interest Ratio / Days to Cover

    Charles River Laboratories International has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Charles River Laboratories International has recently increased by 7.85%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Charles River Laboratories International has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Charles River Laboratories International this week, compared to 11 articles on an average week.
  • Search Interest

    Only 2 people have searched for CRL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Charles River Laboratories International to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Charles River Laboratories International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $92,407.00 in company stock.

  • Percentage Held by Insiders

    Only 1.30% of the stock of Charles River Laboratories International is held by insiders.

  • Percentage Held by Institutions

    98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Charles River Laboratories International's insider trading history.
Receive CRL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.

CRL Stock News Headlines

How to Collect Up To $5,917/mo From Trump’s Made In USA Boom
How to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America. But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month. Don't miss your chance to participate directly in America's industrial comeback.
3 Reasons to Sell CRL and 1 Stock to Buy Instead
See More Headlines

CRL Stock Analysis - Frequently Asked Questions

Charles River Laboratories International's stock was trading at $184.60 at the beginning of the year. Since then, CRL stock has decreased by 15.2% and is now trading at $156.58.
View the best growth stocks for 2025 here
.

Charles River Laboratories International, Inc. (NYSE:CRL) posted its quarterly earnings data on Wednesday, May, 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International's revenue for the quarter was down 2.7% compared to the same quarter last year.
Read the conference call transcript
.

Charles River Laboratories International's board approved a stock buyback program on Wednesday, August 7th 2024, which authorizes the company to buy back $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 9.6% of its shares through open market purchases. Shares buyback programs are often a sign that the company's management believes its stock is undervalued.

Charles River Laboratories International subsidiaries include Vigene Biosciences Inc., Retrogenix Limited, Cognate BioServices, HemaCare, CiToxLAB, MPI Research, KWS BioTest, and others.

Charles River Laboratories International's top institutional shareholders include Confluence Investment Management LLC (0.20%) and Harbor Investment Advisory LLC. Insiders that own company stock include James C Foster, Birgit Girshick, William D Barbo, Joseph W Laplume, Victoria L Creamer, Richard F Wallman, Michael Gunnar Knell, George Massaro and Shannon M Parisotto.
View institutional ownership trends
.

Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Charles River Laboratories International investors own include NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Home Depot (HD) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/07/2025
Today
7/03/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Medical Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:CRL
Employees
20,100
Year Founded
1947

Price Target and Rating

Average Stock Price Target
$171.85
High Stock Price Target
$210.00
Low Stock Price Target
$140.00
Potential Upside/Downside
+9.1%
Consensus Rating
Hold
Rating Score (0-4)
2.19
Research Coverage
16 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
16.83
P/E Growth
5.23
Net Income
$22.20 million
Pretax Margin
0.75%

Debt

Sales & Book Value

Annual Sales
$4.05 billion
Cash Flow
$22.12 per share
Price / Cash Flow
7.12
Book Value
$67.80 per share
Price / Book
2.32

Miscellaneous

Free Float
48,477,000
Market Cap
$7.74 billion
Optionable
Optionable
Beta
1.49

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NYSE:CRL) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners